Nieuw bericht van BBS op YMB:
My call with Vince. As many of you know, I had a call with Vince Anzalone, VP Investor Relations at Arrowhead yesterday, and I wanted to share with you some more details of what I learned. Outside of what was discussed in Arrowhead's last conference call, here's a quick rundown of what I believe were the most relevant takeaways in my call:
1) All three JNJ targets have been identified. While we know that the first target is a liver target, mum's the word on the other two. Mum's also the word on whether those targets include the coronavirus.
2) On the COVID target, I asked if it's 1 or 2 targets, Vince could not comment. The R&D development is being funded by Arrowhead. They are looking into possibly getting government funding - too early to know or to say. As far as when more information will be released, we'll just have to wait and see.
3) HBV data should be coming out at EASL in London, Aug. 25-28th.
4) Regarding Arrowhead's pulmonary drugs, Arrowhead has been working in parallel on a number of new indications, including COPD, asthma, and IPF. They have been able to identify the target for COPD and they are currently working on still identifying targets for asthma and IPF. The company believes this franchise will unfold quickly.
5) Regarding Goldman's $47 price target, Vince said that the research arm of Goldman is separate from the investment banking arm, which explains the discrepancy with the offering price of $58. He likes Goldman's coverage, as there is room for price target increases.
6) As seen by the various road shows, Arrowhead is continually doing what it can to get the word out and to increase ownership of its stock by institutions.
7) While Vince would like to see the stock be at $70 today, he's not worried, as there is so much good stuff going on, and it just takes some time to play out.
That's pretty much it. There were a number of other topics that we discussed, but not relevant or new enough to mention.